Cell line-derived xenograft (CDX) models are among the most commonly used research models for efficacy evaluation of anti-cancer therapies. CDX models are created by implanting cancer cell lines into immunodeficient mice and have contributedsignificantly to the development of cancer drug therapies. The establishment of CDX models involves inoculation of tumor cells (including various types of cancer cells) into immunodeficient mice.
After high-throughput drug screening in vitro, the CDX model is then used for in vivo drug infusion and efficacy evaluations. Due to long-term cell passage in vitro, cells have the characteristics of high homology and reproducibility. However, cell lines often lose their original biological characteristics through many passages. CDXs can be complementary to tumor biopsies and PDXs. CDXs offer an opportunity to generate models for those patients that cannot undergo surgery or an alternative invasive procedure.
Download
Model Type| Cancer Type | Cell Lines |
Brain Cancer | CHP-212, LN-229, U-87 MG, U-118, U-251 MG |
Breast Cancer | BT474, DU4475, HCC1569, HCC1954, HCC70, HCC1806, JIMT-1, MCF7, MDA-MB-231, MDA-MB-436, MDA-MB-468, MX-1, SUM 149PT, ZR-75-1, |
| Cervix | Hela, SiHa |
Colon Cancer | COLO 205, DLD-1, HCT-8, HCT-116, HCT-15, HT-29, KM12-luc, LIM-1215, LoVo, Ls174T, NCI-H716, NCI-H508, RKO, SW48, SW480, SW620, SW837 |
| Endometrium | AN3 CA, HEC-1-A, HEC-1-B, KLE, RL95-2 |
| Esophageal | KYSE-520 |
Fibrosarcoma/Soft Tissue | HT-1080 |
| Gastric | Hs 746T, NCI-N87, MKN-45, SNU-16, NUGC-4 |
Head and Neck | CAL-27, Detroit562, FaDu, TT |
Leukemia | CCRF-CEM, HEL, HL-60, Jurkat E6.1, JVM-3, Kasumi-1, K-562, MOLM-13, MOLM-16, MOLT-3, MOLT-4, MV-4-11, OCI-AML-3, TF-1a, THP-1, U-937 |
Liver Cancer | HCCLM3, Hep G2, HuH-7. |
Lung Cancer | A427, A549, Calu-1, Calu-3, Calu-6, DMS114, EBC-1,HCC827, MSTO-211H, NCI-H69, NCI-H292, NCI-H358, NCI-H460, NCI-H520, NCI-H522, NCI-H526, NCI-H727, NCI-H820, NCI-H838, NCI-H1299, NCI-H1373, NCI-H1568, NCI-H1581, NCI-H1650, NCI-H1703,NCI-H1975, NCI-H2122, NCI-H2228, NCI-H3122, NCI-H3255,PC9 |
| Lymphoma | Daudi, DB,DOHH2,HH,JeKo-1, Karpas299, MAVER-1, Mino, OCI-LY10, OCI-LY19, Raji, RL, SR, SU-DHL-1, SU-DHL-2, SU-DHL-4, SU-DHL-6, TMD-8, WSU DLCL2 |
| Melanoma | A375, C32, SK-MEL-5 |
| Myeloma | MM.1R, MM.1S, NCI-H929, OPM-2, RPMI-8226 |
| Osteosarcoma | SJSA-1 |
| Ovary | A2780, PA-1,OVCAR-3, OVCAR-8, SK-OV-3 |
| Pancreatic | AsPC-1, Bx PC-3, Capan-1, Capan-2, CFPAC-1, HPAC, HPAF-II, Mia PaCa-2, PANC-1, SU.86.86, SW1990 |
| Prostate | 22RV1, DU145, LnCap, LNCaP-F877L mut, PC-3, Vcap |
| Renal | 786-O, A498, ACHN, OS-RC-2 |
Skin | A-431 |
Urinary bladder Cancer | 5637, HT1376, RT4, UM-UC-3 |
Relevant laboratories
Relevant articles
marketing@medicilon.com
